Genomtec S.A., announces that the Extraordinary General Meeting of Shareholders of the company has appointed two new members to the Supervisory Board of the company, effective March 12th, 2024: Gualtiero Garlasco and Beata Turlejska, who will replace Jarosław Oleszczuk and Karol Hop.
Both Mr. Gualtiero Garlasco and Ms. Beata Turlejska will also serve as members of the audit committee in the Supervisory Board of Genomtec.
“Mr. Garlasco is a MedTech industry veteran with extensive experience in general management, commercial operations and business development, making him an invaluable addition to our Board. Ms. Beata Turlejska brings pertinent experience to the Board in developing companies and executing business development transactions in various industries. These new members will greatly support the Management in achieving the strategic goals of the company, which are at an advanced stage of development,” said Miron Tokarski, co-founder and CEO of Genomtec.
Mr. Garlasco brings a wealth of experience and a proven track record in leading business development transformations and driving growth in the diagnostics and life sciences industries to Genomtec, most recently serving as General Manager for Cerus Europe. Prior to his role at Cerus, Mr. Garlasco was Vice President of Global Sales and Marketing for Thermo Fisher Scientific’s Clinical Diagnostics Division where he was responsible for its global commercial activities representing annual sales of approximately $700 million. Previously, he has also held senior leadership roles with Novartis Diagnostics, Ventana Medical Systems and bioMérieux.
“Genomtec is an innovative company with a unique opportunity to attractively position its patented and cost-effective SNAAT® isothermal technology in the point-of-care space both in infectious diseases and oncology. I’m looking forward to supporting the management team to continue their upward trajectory,” said Mr. Garlasco.
Ms. Beata Turlejska is an experienced manager in venture building and leading large companies. Since 2017, she has been a Managing Partner at Leonarto Fund, one of the main shareholders of Genomtec. Previously, she managed one of the largest marketing agencies in Poland, where she was responsible for marketing budgets of clients valued at over PLN 50 million annually. She holds a Master’s degree in Economics with a specialization in finance and is a specialist in human resource management and marketing. She is a graduate of the Warsaw School of Economics and Lazarski University in Warsaw.
“We see immense market potential in projects undertaken by Genomtec, especially its proprietary SNAAT® technology, which could be groundbreaking in detecting mutations in oncology. I will support the Management with my experience in business development transactions and building value for shareholders,” said Beata Turlejska, Managing Partner at Leonarto Fund.
The appointment of two new Supervisory Board members reflects Genomtec’s commitment to strengthening its leadership team and being well equipped to navigate the evolving landscape of the diagnostics industry and drive sustainable growth.
